Author Archives: pierre

On April 1 the 1st ABIRISK Drug Immunogenicity Conference was held in Innsbruck, Austria. There were many highly interesting talks at this meeting, ranging from regulatory perspective by Amy Rosenberg FDA to a mathematical framework for prediction of therapeutic drug immunogenicity by Pfizer. SciCross presented an overview of the ABIRISK database, work that is done in collaboration with the IMI eTRIKS consortia.

The ABIRISK yearly general assembly and workpackage-specific meetings were held in Innsbruck the days before the conference. Here SciCross presented a tool for integration and analysis of data generated in a range of assays focused immunogenicity assessment of biopharmaceuticals. Please feel free to contact us for further discussions on this topic.

SciCross is happy to announce a new collaboration focused on modelling the human blood-brain-barrier using innovative in vitro and stem cell approaches. The project is a collaboration between the University of Skövde, Biolamina, 3Dtro, AstraZeneca and SciCross.

SciCross has contributed to work that will be presented at the European Congress of Immunology 2015, held in Vienna. The titles are ‘Risk factors of anti-drug antibodies (ADA) occurrence in multiple sclerosis ‘ and ‘Antibodies against interferon beta and natalizumab in European multiple sclerosis patients’. This work has been conducted in the scope of the ABIRISK project.

SciCross has received a grant from the Swedish innovation agency VINNOVA for development of innovative methods to reduce drug immunogenicity.

SciCross collaborators within the ABIRISK project will present results at the Scandinavian Society of Immunology meeting in Iceland later this year. The title is “Development of Antidrug Antibodies in Multiple Sclerosis Cohorts in Europe – Overview of Interferon Beta and Natalizumab Cases Tested for ADA in Different Countries”

SciCross has joined the IMI ABIRISK consortia, focused on understanding the mechanisms and consequences of drug immunogenicity of biopharmaceuticals. The project runs until November 2017 and has a total budget of approximately 33M euro.